<p>NewEdge Advisors LLC 在最近向證券交易委員會提交的 13F 表格中披露，其在波士頓科學公司（紐約證券交易所代碼：BSX - 免費報告）的股份在第二季度增加了 14.1%。該基金在此期間額外購買了 13,527 股後，持有該醫療設備提供商的 109,313 股。根據其最近向證券交易委員會的提交，NewEdge Advisors LLC 在波士頓科學的持股價值為 11,741,000 美元。</p>
<p>獲取 <strong>波士頓科學</strong> 警報：</p>
<ul>
<li>注意死亡交叉：3 只股票觸發了這一可怕信號</li>
</ul>
<p>其他幾家機構投資者最近也買賣了該公司的股票。挪威銀行在第二季度新建了波士頓科學的股份，價值 2,089,937,000 美元。Edgewood Management LLC 在第二季度新建了波士頓科學的股份，估計價值約為 746,655,000 美元。貝瑟默集團在第二季度將其在波士頓科學的股份提高了 14,391.8%。貝瑟默集團現在擁有 2,919,801 股該醫療設備提供商的股票，價值 313,618,000 美元，此前在上個季度額外購買了 2,899,653 股。先鋒集團在第二季度將其在波士頓科學的持股增加了 1.9%。先鋒集團現在擁有 137,134,110 股該醫療設備提供商的股票，價值 14,729,575,000 美元，此前在上個季度額外購買了 2,545,381 股。最後，Price T Rowe Associates Inc. MD 在第一季度將其在波士頓科學的股份增加了 18.6%。Price T Rowe Associates Inc. MD 現在擁有 10,610,487 股該醫療設備提供商的股票，價值 1,070,387,000 美元，此前在上個季度額外購買了 1,664,108 股。目前，89.07% 的股票由機構投資者和對沖基金持有。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，董事 Ellen M. Zane 於 11 月 6 日星期四出售了 12,891 股公司的股票。股票以平均價格 98.28 美元出售，總交易額為 1,266,927.48 美元。出售後，該董事持有 24,134 股公司股票，價值 2,371,889.52 美元。這筆交易代表了其持股的 34.82% 的減少。該交易在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，執行副總裁 Arthur C. Butcher 於 12 月 1 日星期一出售了 17,313 股公司的股票。股票以平均價格 101.55 美元出售，總交易額為 1,758,135.15 美元。交易完成後，該執行副總裁持有 23,600 股公司的股票，價值約 2,396,580 美元。這代表了其持股的 42.32% 的減少。該銷售的披露在 SEC 文件中可獲得。在過去的 90 天裏，內部人士已出售 143,095 股公司股票，價值 14,228,950 美元。公司內部人士持有 0.50% 的公司股票。</p>
<h2>波士頓科學價格表現</h2>
<ul>
<li>3 只利用人工智能推動增長的醫療股</li>
</ul>
<p>波士頓科學（NYSE:BSX）週五開盤價為 91.60 美元。該公司的 50 日移動平均線為 98.95 美元，200 日移動平均線為 101.73 美元。該公司的市值為 1357.9 億美元，市盈率為 48.98，PEG 比率為 1.87，貝塔值為 0.67。該公司的債務與股本比率為 0.47，速動比率為 0.96，流動比率為 1.51。波士頓科學公司的 1 年低點為 85.98 美元，1 年高點為 109.50 美元。</p>
<p>波士頓科學（NYSE:BSX - 獲取免費報告）最近於 10 月 22 日星期三發佈了季度收益數據。該醫療設備提供商報告本季度每股收益（EPS）為 0.75 美元，超出市場共識預期的 0.71 美元，超出 0.04 美元。波士頓科學的股本回報率為 19.46%，淨利潤率為 14.43%。該公司本季度的收入為 50.7 億美元，而分析師預期為 49.7 億美元。在去年同期，該公司每股收益為 0.63 美元。該公司本季度的收入同比增長 20.3%。波士頓科學已將其 2025 財年的指引設定為每股收益 3.020-3.040 美元，2025 年第四季度的指引設定為每股收益 0.770-0.790 美元。研究分析師預計波士頓科學公司今年將發佈 2.85 美元的每股收益。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>3 個生物技術催化劑帶來重大機會</li>
</ul>
<p>幾位股票分析師最近對 BSX 股票發表了評論。瑞銀集團將波士頓科學的股票目標價從 135.00 美元上調至 140.00 美元，並在 10 月 23 日星期四的研究報告中給予該公司 “買入” 評級。羅伯特·W·貝爾德將波士頓科學的股票目標價從 123.00 美元上調至 128.00 美元，並在 10 月 1 日星期三的研究報告中給予該股票 “跑贏大盤” 評級。加拿大皇家銀行在 9 月 29 日星期一的報告中重申了 “跑贏大盤” 評級，並設定波士頓科學的股票目標價為 125.00 美元。Cowen 在研究報告中重申了波士頓科學的 “買入” 評級。最後，富國銀行將波士頓科學的目標價從 124.00 美元上調至 125.00 美元，並在 10 月 23 日星期四的研究報告中給予該公司 “增持” 評級。兩位研究分析師對該股票給予了強烈買入評級，二十一位給予了買入評級，二位給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 124.43 美元。</p>
<p><strong>查看我們最新的波士頓科學股票分析</strong></p>
<h2>波士頓科學公司簡介</h2>
<p>（免費報告）</p>
<p>波士頓科學公司開發、製造和銷售用於全球各類介入醫學專業的醫療設備。它通過兩個部門運營，分別是醫療外科和心血管。該公司提供用於診斷和治療胃腸和肺部疾病的設備，如解決夾、膽道支架系統、支架和電切增強輸送系統、直接可視化系統、數字導管和一次性十二指腸鏡；用於治療泌尿系統疾病的設備，包括輸尿管支架、導管、籃子、導絲、鞘、氣囊、一次性數字柔性輸尿管鏡、霍爾米激光系統、人工尿道括約肌、激光系統、光纖和水凝膠系統；以及用於治療神經運動障礙和管理慢性疼痛的設備，如脊髓刺激器系統、專有編程軟件、射頻發生器、間接減壓系統、實踐優化工具和深腦刺激系統。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過波士頓科學</li>
<li>3 只防御類股票將受益於軍事支出增加</li>
<li>3 只最近被下調評級的股票，2026 年應避免</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>芯片熱潮迴歸：3 只股票有望獲得巨大收益</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>甲骨文股票遭重創：為何其人工智能管道可能推動 2026 年反彈</li>
</ul>
<p><strong>想看看其他對 BSX 感興趣的對沖基金持有什麼嗎？</strong> 請訪問 HoldingsChannel.com，獲取波士頓科學公司（NYSE:BSX - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在波士頓科學嗎？</h2>
<p>在考慮波士頓科學之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而波士頓科學並不在名單上。</p>
<p>雖然波士頓科學目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

波士頓科學

<p>NewEdge Advisors LLC 在第二季度將其在波士頓科學公司的股份增加了 14.1%，目前持有 109,313 股，價值 1174 萬美元。其他主要投資者如挪威銀行和先鋒集團也調整了他們的持倉。內部人士最近出售了大量股份。波士頓科學的第三季度收益超出預期，年同比收入增長 20.3%。分析師們提高了價格目標，表明公司有積極的增長前景</p>

<p>NewEdge Advisors LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 14.1% in the second quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 109,313 shares of the medical equipment provider's stock after acquiring an additional 13,527 shares during the period. NewEdge Advisors LLC's holdings in Boston Scientific were worth $11,741,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>NewEdge Advisors LLC 在最近向證券交易委員會提交的 13F 表格中披露，其在波士頓科學公司（紐約證券交易所代碼：BSX - 免費報告）的股份在第二季度增加了 14.1%。該基金在此期間額外購買了 13,527 股後，持有該醫療設備提供商的 109,313 股。根據其最近向證券交易委員會的提交，NewEdge Advisors LLC 在波士頓科學的持股價值為 11,741,000 美元。</p>
</div><p>Get <strong>Boston Scientific</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>波士頓科學</strong> 警報：</p>
</div><ul>
<li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>注意死亡交叉：3 只股票觸發了這一可怕信號</li>
</ul>
</div><p>Several other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Boston Scientific during the second quarter worth $2,089,937,000. Edgewood Management LLC acquired a new position in Boston Scientific during the 2nd quarter valued at about $746,655,000. Bessemer Group Inc. raised its stake in Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider's stock valued at $313,618,000 after buying an additional 2,899,653 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也買賣了該公司的股票。挪威銀行在第二季度新建了波士頓科學的股份，價值 2,089,937,000 美元。Edgewood Management LLC 在第二季度新建了波士頓科學的股份，估計價值約為 746,655,000 美元。貝瑟默集團在第二季度將其在波士頓科學的股份提高了 14,391.8%。貝瑟默集團現在擁有 2,919,801 股該醫療設備提供商的股票，價值 313,618,000 美元，此前在上個季度額外購買了 2,899,653 股。先鋒集團在第二季度將其在波士頓科學的持股增加了 1.9%。先鋒集團現在擁有 137,134,110 股該醫療設備提供商的股票，價值 14,729,575,000 美元，此前在上個季度額外購買了 2,545,381 股。最後，Price T Rowe Associates Inc. MD 在第一季度將其在波士頓科學的股份增加了 18.6%。Price T Rowe Associates Inc. MD 現在擁有 10,610,487 股該醫療設備提供商的股票，價值 1,070,387,000 美元，此前在上個季度額外購買了 1,664,108 股。目前，89.07% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, Director Ellen M. Zane sold 12,891 shares of the firm's stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company's stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 143,095 shares of company stock worth $14,228,950. Corporate insiders own 0.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Ellen M. Zane 於 11 月 6 日星期四出售了 12,891 股公司的股票。股票以平均價格 98.28 美元出售，總交易額為 1,266,927.48 美元。出售後，該董事持有 24,134 股公司股票，價值 2,371,889.52 美元。這筆交易代表了其持股的 34.82% 的減少。該交易在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，執行副總裁 Arthur C. Butcher 於 12 月 1 日星期一出售了 17,313 股公司的股票。股票以平均價格 101.55 美元出售，總交易額為 1,758,135.15 美元。交易完成後，該執行副總裁持有 23,600 股公司的股票，價值約 2,396,580 美元。這代表了其持股的 42.32% 的減少。該銷售的披露在 SEC 文件中可獲得。在過去的 90 天裏，內部人士已出售 143,095 股公司股票，價值 14,228,950 美元。公司內部人士持有 0.50% 的公司股票。</p>
</div><h2>Boston Scientific Price Performance</h2>
<div class="lb-trans"><h2>波士頓科學價格表現</h2>
</div><ul>
<li>3 Healthcare Stocks Using AI to Drive Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只利用人工智能推動增長的醫療股</li>
</ul>
</div><p>NYSE:BSX opened at $91.60 on Friday. The firm's fifty day moving average is $98.95 and its two-hundred day moving average is $101.73. The firm has a market cap of $135.79 billion, a price-to-earnings ratio of 48.98, a PEG ratio of 1.87 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50.</p>
<div class="lb-trans"><p>波士頓科學（NYSE:BSX）週五開盤價為 91.60 美元。該公司的 50 日移動平均線為 98.95 美元，200 日移動平均線為 101.73 美元。該公司的市值為 1357.9 億美元，市盈率為 48.98，PEG 比率為 1.87，貝塔值為 0.67。該公司的債務與股本比率為 0.47，速動比率為 0.96，流動比率為 1.51。波士頓科學公司的 1 年低點為 85.98 美元，1 年高點為 109.50 美元。</p>
</div><p>Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analysts' expectations of $4.97 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The company's revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.</p>
<div class="lb-trans"><p>波士頓科學（NYSE:BSX - 獲取免費報告）最近於 10 月 22 日星期三發佈了季度收益數據。該醫療設備提供商報告本季度每股收益（EPS）為 0.75 美元，超出市場共識預期的 0.71 美元，超出 0.04 美元。波士頓科學的股本回報率為 19.46%，淨利潤率為 14.43%。該公司本季度的收入為 50.7 億美元，而分析師預期為 49.7 億美元。在去年同期，該公司每股收益為 0.63 美元。該公司本季度的收入同比增長 20.3%。波士頓科學已將其 2025 財年的指引設定為每股收益 3.020-3.040 美元，2025 年第四季度的指引設定為每股收益 0.770-0.790 美元。研究分析師預計波士頓科學公司今年將發佈 2.85 美元的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>3 Biotech Catalysts Present Major Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>3 個生物技術催化劑帶來重大機會</li>
</ul>
</div><p>Several equities analysts recently commented on BSX shares. UBS Group increased their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 23rd. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, October 1st. Royal Bank Of Canada reissued an &#34;outperform&#34; rating and set a $125.00 price objective on shares of Boston Scientific in a report on Monday, September 29th. Cowen restated a &#34;buy&#34; rating on shares of Boston Scientific in a research note on Thursday. Finally, Wells Fargo &amp; Company boosted their price target on Boston Scientific from $124.00 to $125.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average price target of $124.43.</p>
<div class="lb-trans"><p>幾位股票分析師最近對 BSX 股票發表了評論。瑞銀集團將波士頓科學的股票目標價從 135.00 美元上調至 140.00 美元，並在 10 月 23 日星期四的研究報告中給予該公司 “買入” 評級。羅伯特·W·貝爾德將波士頓科學的股票目標價從 123.00 美元上調至 128.00 美元，並在 10 月 1 日星期三的研究報告中給予該股票 “跑贏大盤” 評級。加拿大皇家銀行在 9 月 29 日星期一的報告中重申了 “跑贏大盤” 評級，並設定波士頓科學的股票目標價為 125.00 美元。Cowen 在研究報告中重申了波士頓科學的 “買入” 評級。最後，富國銀行將波士頓科學的目標價從 124.00 美元上調至 125.00 美元，並在 10 月 23 日星期四的研究報告中給予該公司 “增持” 評級。兩位研究分析師對該股票給予了強烈買入評級，二十一位給予了買入評級，二位給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 124.43 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Boston Scientific</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的波士頓科學股票分析</strong></p>
</div><h2>Boston Scientific Company Profile</h2>
<div class="lb-trans"><h2>波士頓科學公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.</p>
<div class="lb-trans"><p>波士頓科學公司開發、製造和銷售用於全球各類介入醫學專業的醫療設備。它通過兩個部門運營，分別是醫療外科和心血管。該公司提供用於診斷和治療胃腸和肺部疾病的設備，如解決夾、膽道支架系統、支架和電切增強輸送系統、直接可視化系統、數字導管和一次性十二指腸鏡；用於治療泌尿系統疾病的設備，包括輸尿管支架、導管、籃子、導絲、鞘、氣囊、一次性數字柔性輸尿管鏡、霍爾米激光系統、人工尿道括約肌、激光系統、光纖和水凝膠系統；以及用於治療神經運動障礙和管理慢性疼痛的設備，如脊髓刺激器系統、專有編程軟件、射頻發生器、間接減壓系統、實踐優化工具和深腦刺激系統。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Boston Scientific</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過波士頓科學</li>
<li>3 只防御類股票將受益於軍事支出增加</li>
<li>3 只最近被下調評級的股票，2026 年應避免</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>芯片熱潮迴歸：3 只股票有望獲得巨大收益</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>甲骨文股票遭重創：為何其人工智能管道可能推動 2026 年反彈</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BSX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 BSX 感興趣的對沖基金持有什麼嗎？</strong> 請訪問 HoldingsChannel.com，獲取波士頓科學公司（NYSE:BSX - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在波士頓科學嗎？</h2>
</div><p>Before you consider Boston Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮波士頓科學之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而波士頓科學並不在名單上。</p>
</div><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然波士頓科學目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

NewEdge Advisors LLC 增加了其在波士頓科學公司 $BSX 的股票持倉